Abstract
The polymorphism rs16754 of the WT1 gene has been described as a possible prognostic marker in different acute myeloid leukemia (AML) cohorts; however, it is not supported by all the studies. We performed the first meta-analysis evaluating the effect of this polymorphism upon the effectiveness of standard AML therapy. Fourteen cohort studies were included (3618 patients). Patients with the variant allele showed a significant higher overall survival (OS) at 5 years (OR:1.24, 95% CI: 1.06–1.45, P=0.007, with dominant model). WT1 did not influence complete remission, but a higher disease-free survival was observed with the variant allele. In the subgroup analysis, Caucasians, pediatric and patients treated with idarubicin and etoposide carrying the variant allele showed consistent results in OS, whereas patients with cytogenetically normal AML did not show differences. To verify the effect of this polymorphism upon other outcomes, studies in larger and multiracial populations are needed.
Similar content being viewed by others
Introduction
Acute myeloid leukemia (AML) is a clinically and biologically heterogeneous disease characterized cytogenetically by recurrent abnormalities, which provide powerful prognostic information.1 Cytogenetically normal AML (CN-AML) is the largest subgroup, representing ~45% of adult patients with AML.2 In the last years, emerging data have indicated that somatic mutations are associated with treatment outcome and serve as a basis for molecularly guided risk assessment and treatment stratification.3, 4, 5, 6, 7
Mutations in the Wilms tumor 1 gene (WT1) occur in ~10% of adults with CN-AML8 and are potential markers in AML. Although these mutations are predicted to lead to loss of function of WT1 with several studies reporting a worse outcome,9, 10, 11, 12, 13, 14, 15 other authors found that these mutations have no prognostic impact.16, 17, 18
The WT1 gene, located on chromosome band 11p13, encodes a zinc-finger transcription factor, which has emerged as an important regulator of normal and malignant hematopoiesis. Originally, WT1 was identified as a tumor-suppressor gene isolated in Wilms tumor,19 a pediatric kidney malignancy. However, accumulating data revealed that WT1 appears to have an oncogenic rather than tumor-suppressor role.20 Although the WT1 role in hematopoiesis has not been clarified, expression was inversely associated with stem cell proliferation and differentiation.21
Almost all leukemia-associated WT1 mutations occur within the zinc-finger domains; mainly within a hotspot in exon 7. This exon is the location of the synonymous single-nucleotide polymorphism (SNP) rs16754 that results in adenine (A) or guanine (G) containing alleles. The frequencies of these alleles vary between ethnic groups, so that G is the minor allele in Caucasians and the major allele in Asian populations.22 WT1 polymorphism does not seem to increase susceptibility to AML, with similar frequency between healthy volunteers and AML patients.17 This synonymous SNP may affect to treatment outcome with different potential mechanisms, as alterations in RNA expression, stability, splicing and binding and changes in translational kinetics,23 or on the other hand it could be in linkage disequilibrium with a functional SNP. As for WT1 mutation, several publications have investigated the prognostic impact of WT1 rs16754 SNP in AML cohorts producing non-conclusive or contradictory results.17, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37
Considering that WT1 rs16754 SNP may have a promising albeit inconclusive role in AML treatment, we carried out a meta-analysis on all eligible observational studies to estimate the effect of WT1 polymorphism on AML patients and to quantify the potential between-study heterogeneity.
Materials and methods
Search strategy and selection of studies
This meta-analysis and systematic review was conducted and reported in accordance with the PRISMA guidelines (Preferred Reporting Items for Systematic Reviews and Meta-analyses)38 by two independent authors (JM and MH).
We searched the following databases without restrictions: MEDLINE, Cochrane Central Register, EMBASE, Web of Science and Database of Abstracts of Reviews of Effects (DARE), ProQuest Medical Library, EBSCOhost Online Research Databases, WanFang and Chinese National Knowledge Infraestructure (CNKI) and LILACS. There were no limitations in language, date or status publication restrictions. Additional studies were identified by manual search of the following journals: Leukemia, Cancer, British Journal of Haematology, Blood, Lancet, Lancet Oncology, Journal of Clinical Oncology, Pharmacogenomics, Pharmacogenomics Journal and Pharmacogenetics and Genomics. Congress abstracts of the American Society of Hematology (ASH), the European Hematology Association (EHA) and the Spanish Society of Hematology and Hemotherapy (SEHH) were reviewed. We also hand searched the reference lists of important studies and reviews. The literature last search was on 4 June 2015.
Similar keywords were used in different databases: WT1 (or wilms tumor gen or rs16754), AML and polymorphism (or single-nucleotide or SNP or genetic polymorphisms or pharmacogenetics).
Study selection was conducted by both authors independently. In case of disagreement a third reviewer (LR) was contacted. Studies that fulfilled the following criteria were included: (1) AML studies using standard induction (including cytarabine, anthracyclines and/or etoposide); (2) studies containing useful genotype frequencies of WT1 rs16754 polymorphism; (3) studies evaluating the association of the WT1 polymorphism and AML outcomes; (4) in vivo studies. Studies that included patients with promyelocytic leukemias (FAB subtype M3) were excluded since these leukemias were treated with different regimens.
Data extraction
Information was extracted independently by two reviewers. From included studies the following data was extracted (summarized in Table 1): characteristics of the study (language, publication status and methodological quality), patients baseline characteristics (sex, median age, ethnic origen, AML status, FAB subtype, diagnosis white blood cells (WBC), cytogenetics and main mutations), chemotherapy scheme and polymorphism frequencies of rs16754 SNP (A>G) and if they are in accordance with Hardy–Weinberg equilibrium, as well as genotyping method. We also collected effectiveness outcomes: mean overall survival (OS), complete remission (CR) and others.
Three authors were contacted to request missing information regarding outcomes, but the response was not received and we inferred the effectiveness data with the available information (like Kaplan–Meier graphs or number of events), when possible.
Methodological quality
Two reviewers (JM and MH) independently assessed the methodological quality of the included studies. Disagreements were recorded and resolved by a third reviewer (LR). Kappa statistics were used to evaluate reviewers agreement. Criteria used were showed in Table 2.
We define the risk of bias with the following criteria: low risk if all criteria were met, moderate risk if only one was not met, and high risk if the number of unmet criteria were two or more.
Analysis
The influence of the WT1 rs16754 genotypes and effectiveness variables was evaluated by pooled odds ratios (OR) and 95% confidence interval (95% CI) using the fixed effects (Mantel–Haenszel method). The statistical significance of pooled OR were determined with Z test (values of P<0.05 were considered statistically significant). RevMan software (version 5.2 The Cochrane Collaboration, The Nordic Cochrane Center, Copenhagen, Denmark) was used to conduct this meta-analysis. The association between AML outcomes and WT1 rs16754 genotypes was performed using dominant (AA vs AG/GG) and recessive models (AA/AG vs GG).
Statistical heterogeneity across studies was tested using the χ2-test (heterogeneity if P<0.1) and the I2 statistic (significant heterogeneity when I2>50%). If heterogeneity was present, the meta-analysis was repeated using the random effects model.
Subgroup analyses were performed for effectiveness variables (OS and CR) based on the ethnicity, age and chemotherapy scheme of the patients. Other predefined variables (included in Table 1) were not analyzed because the information provided by authors was not related with the genotype frequencies and effectiveness variables. We also analyzed OS and CR in patients with CN-AML. Differences between subgroups were evaluated with interaction test (chi-squared).
The possibility of publication bias was conducted evaluating the funnel plots symmetry and with Egger's test (statistical significance if P<0.1).
Results
Systematic search obtained 201 citations from databases and journals and 8 records identified through other sources (Figure 1). Of the 43 citations selected for full reading, only 14 fulfilled the inclusion criteria and were included (all in English). Reviewers showed an excellent agreement in study selection (kappa=0.91).
The OS at some of the analyzed times was inferred from the Kaplan–Meier plots in eight studies.24, 25, 29, 30, 31, 34, 37
Study and patient characteristics
Fourteen cohort studies were included (3618 patients).17, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37 The characteristics of the individual studies included are provided in Table 1. Patients’ mean age was 35.4 years (range of 1–88 years) and they were males in 53.5% of the cases. Three studies did not include age or gender data.24, 25, 28 The most abundant ethnic group was Caucasian (72%), followed by Asian (14.7%). Concerning AML, 95.5% were de novo AML and the predominant FAB subtypes represented were M2 (30.9%), M4 (24.7%) and M1 (19.6%). Normal cytogenetic risk was present in 70.4% of patients, whereas 18% had favorable risk and 11.5% had unfavorable one. Mutations were evaluated in nine studies17, 27, 30, 31, 32, 33, 34, 35, 36 and they are summarized in Table 1.
Genotype distributions were in accordance with the Hardy–Weinberg equilibrium in most studies, with three exceptions27, 30, 31 and there were two studies without genotype frequencies.24, 25 The method used for genotyping consisted of PCR and direct sequencing in eight studies,24, 28, 29, 30, 31, 33, 35, 36 real-time reverse transcriptase PCR in four studies,17, 25, 32 mass spectrometry and PCR-restriction fragment length polymorphism to validate in one study37 and two different methods in the last study.34 The baselines characteristics and evaluable AML outcomes for included studies concerning WT1 rs16754 polymorphism are listed in Table 1.
Risk of bias
Only three of the included studies met all 9 criteria and were classified as low risk of bias.17, 32, 37 Eight studies met 8 criteria (intermediate risk of bias).27, 28, 30, 31, 33, 34, 35, 36 The other three studies were categorized as high risk of bias, one met 7 criteria24 and two studies met 6 criteria25, 29 (Table 2). Reviewers showed a substancial agreement (kappa=0.66).
Overall survival
OS for rs16 754 polymorphism was analyzed in 14 studies (Table 1) with 3618 total patients,17, 24, 25, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37 10 of them included enough data to evaluate the recessive model (2875 patients).17, 24, 27, 30, 31, 32, 33, 35, 36, 37 We evaluated OS at 3 and 5 years and calculated OR and 95% CI (Table 3). Two studies only reported OS at 3 years30, 31 and we inferred these data as OS at 5 years. Percentage of OS at 5 years was estimated through Kaplan–Meier graphs in 8 studies that estimated OS at >5 years24, 25, 29, 30, 31, 34, 36, 37 and 8 studies for OS estimations at 3 years.17, 24, 25, 29, 33, 34, 36, 37
We found evidence indicating that the variant allele G is associated with higher OS (Table 3). Statistical significance was obtained with the dominant model (OR: 1.24, 95% CI: 1.06–1.45, P=0.007, I2: 67%; Figure 2). Significant heterogeneity was detected using the fixed-effect model and the meta-analyses were repeated using the random-effect model (OR: 1.19, 95% CI: 0.86–1.63, I2: 67%, P: 0.30) in which statistical significance was lost. This association was not replicated with recessive model as well as the analysis of OS at 3 years (Table 3).
The analysis for publication bias showed a little asymmetry in funnel plot of dominant model, as the studies of Damm et al.17 and Becker et al.35 were slightly out the funnel in the dominant model, but this was not significant in the Egger’s test (P=0.65 for OS at 5 years and P=0.76 at 3 years).
Complete remission
Ten studies evaluated CR for WT1 polymorphism17, 27, 30, 31, 32, 33, 34, 35, 36, 37 with 2793 total patients. The pooled effect estimate did not show association between CR and WT1 genotypes in dominant (OR: 1.10, 95% CI: 0.89–1.37, P=0.38, I2: 0%; Table 3) or recessive model (OR: 0.80, 95% CI: 0.58–1.11, P=0.18, I2: 7%; Table 3).
The publication bias analysis yielded nonsignificant asymmetry in funnel plot (though Renneville et al.33 was a bit out the funnel in recessive model) as well as in the Egger’s test (P=0.74).
Other effectiveness variables
The included studies analyzed other effectiveness variables (Table 3), as relapse-free survival (RFS) (5 studies, 703 patients),17, 31, 34, 36, 37 disease-free survival (DFS; 4 studies, 1303 patients)27, 29, 34, 35 and rate of relapse (RR; 5 studies, 1387 patients).27, 30, 31, 33, 36 Two studies evaluated event-free survival32, 36 and other two studies analyzed treatment-related mortality,27, 28 but the limited data published did not allow to measure these variables.
We evaluated separately these variables at 5 years with dominant and recessive models (Table 3). We estimated RFS at 5 years in 4 studies31, 34, 36, 37 and DFS at 5 years in 2 studies,30, 34 using the Kaplan–Meier graphs.
We did not find any difference in RFS and RR for this SNP with both models. The pooled effect estimate showed a higher DFS in G allele carriers, statistically significant in the recessive model (OR: 1.77, 95% CI: 1.09–2.86, P=0.02, I2: 5%).
Subgroup analysis
Ethnics: An interaction between OS and ethnic origen for WT1 was found with the dominant model (Table 4). Caucasian participants carrying G allele showed statistically significant higher OS (OR: 1.21, 95% CI: 1.01–1.45, P=0.04, I2: 75%; Figure 3), but with significant heterogeneity. We recalculated with random effects (OR: 1.27, 95% CI: 0.86–1.87, P=0.24, I2: 75%). Regarding CR, no significant associations were found.
Age: Pediatric patients carrying G allele showed statistically significant higher OS with the recessive model (OR: 1.42, 95% CI: 1.14–1.77, P=0.002, I2: 60%; Figure 4). It was reanalyzed with random effects model (OR: 1.24, 95% CI: 0.80–1.92, I2: 60%, P: 0.33). We found no significant correlations regarding CR (Table 4). Evaluation of publication bias was nonsignificant in all comparisions.
CN-AML: Our results did not demonstrate an effect of WT1 genotypes in OS and CR with dominant or recessive model in AML patients with normal cytogenetics (Table 4).
Chemotherapy scheme: All the studies included in this systematic review employed cytarabine plus anthracyclines with or without etoposide (Table 1). Patients with G allele treated with idarubicin (OR: 1.38, 95% CI: 1.16–1.65, P=0.0003, I2: 71%; Figure 5) showed higher OS with the dominant model, but this effect was not reproducible with daunorubicin schemes and was lost with random effects model (OR: 1.38, 95% CI: 0.94–2.02, I2: 71%, P: 0.10). Regarding etoposide schemes, the variant allele was associated with higher OS in patients treated with etoposide (OR: 1.74, 95% CI: 1.40–2.15, P<0.00001, I2: 63%; Figure 5) and the opposite effect in treatments without etoposide (OR: 0.79, 95% CI: 0.61–1.02, P=0.07, I2: 0%; Figure 5). In this association a significant heterogeneity was detected and random effects analysis was performed (OR: 1.78, 95% CI: 1.17–2.72, I2: 63%, P: 0.007; Table 4). No significant correlations were found with CR (Table 4).
Sensitivity analyses
After excluding outlier studies17, 35 significant differences were not found in OS analysis (OR: 1.23, 95% CI: 1.04–1.47, P=0.02, I2: 52%), denoting that our results are robust and reliable. The pooled effect estimated with fixed or random-effect models did not show significant discrepancies (Table 3).
The studies of Chen et al.31 and Luo et al.30 are the only two studies that evaluated OS at 3 years. No differences were obtained after their exclusion in OS with both models.
Discussion
The findings of this meta-analysis suggest that the WT1 rs16754 polymorphism in AML could influence the standard chemotherapy effectiveness, specifically the variant allele (G) could be associated with increased OS. Our results suggest that the variant genotype of WT1 SNP increased OS, with statistical significance using the dominant model, although the slight increase in OR reveals that the clinical impact of the variant genotype could be limited. In Caucasian and pediatric patients this effect was more manifest. We found significant heterogeneity in OS analysis with the dominant model, and we recalculated this analysis with random effects and statistical significance was lost. This heterogeneity was introduced by two studies,17, 35 which were performed only in CN-AML patients, thus providing a reason for this heterogeneity. The exclusion of these studies in the sensitivity analysis produced a decrease in heterogeneity, whereas significant results in OS were maintained. Similar results with variant G allele were obtained with DFS.
We did not observe any significant effect for CR, possibly as a consequence of the small number of studies that evaluated it. These results were consistent with the CR obtained in the individual studies, all of them without significant differences in this outcome. Other variables related with CR, such as RFS and RR, showed similar values after meta-analysis.
The reason for the increase in survival rates associated with the variant allele of rs16754 remains undetermined. Several action mechanisms have been proposed to explain how this synonymous SNP may alter protein amount, structure and/or activity of WT1. This polymorphism consists of the replacement of CGA by CGG codon, and the latter is used two times more often than the former to encode arginine.39 Therefore, the presence of G allele is predicted to increase the rate of translation, which could potentially affect protein folding. A second possibility is that SNP rs16754 is in linkage disequilibrium with another genetic variant that affects drug metabolism, although only few studies40, 41, 42 reported tag SNPs of WT1 gene (any of them in AML patients), and only one of them40 found other WT1 polymorphisms in linkage disequilibrium with rs16754. A third possibility is that this SNP can affect the sensitivity or timing of co-translational folding and binding of non-coding RNAs. In other synonymous polymorphism, such as C3435T SNP of the multidrug resistance 1 (ABCB1) gene, the variant has been postulated to change P-glycoprotein substrate and inhibitor interaction sites.43 Other explanation could be that GG genotype was more sensitive to cytarabine, and therefore this genotype conferred a favorable outcome in treatment with high-dose cytarabine.17
Although some studies associated the presence of G allele with an increase in WT1 expression,27, 30, 37 this relation is not completely understood. One of these studies30 also demonstrated that GG genotype did not predict improved outcome in stratified groups according to the median expression of WT1. This fact and the contradictory data exposed in other studies17, 32 suggest that the influence on WT1 expression of WT1 SNP rs16754 is not as significant as that of other genetic or nongenetic factors. The subgroup analysis by ethnic origin showed similar results in different races in OS and CR. The opposite genotype frequencies in Asian and Caucasian populations are well known. Specifically, G is a minor allele in Western populations, whereas it is a major allele in Asian populations. Nevertheless, the effect of this SNP in AML outcomes seems to be equivalent in both ethnic groups. Caucasian patients were the unique ethnic origin that obtained statistical significant increase of OS related with variant allele. The impact of this polymorphism in other races remains poorly studied.
The age subgroup analysis found a significant relation between variant allele and higher OS in pediatric patients, not detected in adults. This association was not reproduced with the recessive model, possibly because of the limited number of studies and their contradictory results. Only one study29 compared WT1 SNPs in both age subgroups directly, in which AG genotype was associated with shorter OS and EFS in pediatric patients, but not in adults. These results are contradictory with ours, but it should be noted that this study included a small cohort of Arabic patients undergoing allogeneic stem cell transplant.
Another factor that could explain result variability among studies could be the variability in AML induction therapy. Chemotherapy schemes used in eligible studies were based on cytarabine and anthracyclines. Previous studies did not find differences in the type of anthracycline used and the effect of WT1 polymorphisms. We obtained a significant higher OS with G allele in patients treated with idarubicin, not observed in daunorubicin treatments. Similar results were found with etoposide schemes. These studies mixed different chemotherapy agents, even both anthracyclines, therefore it is difficult to clearly differentiate the drug effect of the schemes employed.
Heterogeneity could difficult the interpretation of the pooled estimations of meta-analyses. We repeated the meta-analysis using the random effects model when heterogeneity was present, and significant results were lost in most of these analyses, therefore limiting their clinical implications. This model involves an assumption that the effects being estimated in the different studies are not identical, but follow some kind of distribution, and it is the appropriate model when heterogeneity is present. In our results, heterogeneity was identified in one of the statistical significant results, which was introduced by two studies17, 35 that only included CN-AML patients in their analysis. After excluding these studies in a post hoc analysis, the heterogeneity decreased while maintaining the OS significant results. Our subgroup analysis of CN-AML patients reveals that WT1 polymorphism does not influence OS or CR. Unfortunately we could analyze the impact of this SNP in other cytogenetic risk groups, such as high-risk or core binding factor leukemia. The ethnic and chemotherapy scheme subgroup analyses showed similar heterogeneity, probably related with the two previously cited studies.17, 35
Some limitations of this meta-analysis should be addressed. First, the role of WT1 in the development of AML and its effect in treatment outcomes are not completely understood. Second, our results are based on unadjusted estimates, whereas a more precise analysis should be conducted if more detailed individual data were available. Third, we found that genotype distributions were not in agreement with Hardy–Weinberg equilibrium in three studies27, 30, 31 and unknown in other two studies.24, 25 Fourth, regarding the subgroup analysis, we find novel associations with G allele of rs16754 and OS that generate new hypothesis but that we cannot explain properly. Finally, subgroup analyses regarding other variables (sex, AML and mutation status, and so on) were not performed due to insufficient data available in the original studies.
WT1 rs16754 polymorphism has never been formerly meta-analyzed and individual studies have shown inconclusive results. Our meta-analysis consisted in the use of extensive search strategies of the literature together with selection criteria. Effectiveness variables were extracted and their pooled effects were estimated with appropriate statistical analyses. Likewise, results obtained were demonstrated to be robust in posterior sensitivity analyses.
In summary, this meta-analysis showed an association between rs16754 polymorphism and OS with fixed effects, but the statistical significance was lost with random effects model. This effect was especially shown in subgroups of Caucasian patients, pediatric patients, and those receiving combined idarubicin-etoposide treatments. The polymorphism showed no association with CR. Future studies based on larger populations and using different age, ethnic and cytogenetic groups should clarify the effect of WT1 in AML outcomes, as well as its influence in different chemotherapy schemes. Moreover, further studies that investigate gene–gene and gene–environment interactions may help understand the role of WT1 in the chemotherapy effectiveness.
References
Bloomfield CD, Lawrence D, Byrd JC, Carroll A, Pettenati MJ, Tantravahi R et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukemia varies by cytogenetic subtype. Cancer Res 1998; 58: 4173–4179.
Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: A Southwest Oncology Group/ Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075–4083.
Rombouts WJ, Blokland I, Lowenberg B, Ploemacher RE . Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the Flt3 gene. Leukemia 2000; 14: 675–683.
Schnittger S, Schoch C, Kern W, Mecucci C, Tschulik C, Martelli MF et al. Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 2005; 106: 3733–3739.
Preudhomme C, Sagot C, Boissel N, Cayuela JM, Tigaud I, de Botton S et al. Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: A study from the Acute Leukemia French Association (ALFA). Blood 2002; 100: 2717–2723.
Whitman SP, Liu S, Vukosavljevic T, Rush LJ, Yu L, Liu C et al. The MLL partial tandem duplication: Evidence for recessive gain-of-function in acute myeloid leukemia identifies a novel patient subgroup for molecular targeted therapy. Blood 2005; 106: 345–352.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009; 114: 937–951.
King-Underwood L, Renshaw J, Pritchard-Jones K . Mutations in the Wilms’ tumor gene WT1 in leukemias. Blood 1996; 87: 2171–2179.
Summers K, Stevens J, Kakkas I, Smith M, Smith LL, Macdougall F et al. Wilms’ tumour 1 mutations are associated with FLT3-ITD and failure of standard induction chemotherapy in patients with normal karyotype AML. Leukemia 2007; 21: 550–551.
Paschka P, Marcucci G, Ruppert AS, Whitman SP, Mrózek K, Maharry K et al. Wilms’ tumor 1 gene mutations independently predict poor outcome in adults with cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. J Clin Oncol 2008; 26: 4595–4602.
Virappane P, Gale RA, Hills R, Kakkas I, Summers K, Stevens J et al. Mutations of the Wilms’ tumor 1 gene is a poor prognostic factor associated with chemoresistance in normal karyotype acute myeloid leukemia: the United Kingdom Medical Research Council Adult Leukaemia Working Party. J Clin Oncol 2008; 26: 5429–5435.
Renneville A, Boissel N, Zurawski V, Llopis L, Biggio V, Nibourel O et al. Wilms tumor 1 gene mutations are associated with a higher risk of recurrence in young adults with acute myeloid leukemia: a study from the Acute Leukemia French Association. Cancer 2009; 115: 3719–3727.
Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M et al. Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia. Blood 2009; 113: 5951–5960.
Becker H, Marcucci G, Maharry K, Radmacher MD, Mrózek K, Margeson D et al. Mutations of the Wilms tumor 1 geneWT1 in older patients with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Blood 2010; 116: 788–792.
Hou H-A, Huang T-C, Lin L-I, Liu C-Y, Chen C-Y, Chou W-C et al. WT1 mutation in 470 adult patients with acute myeloid leukemia: stability during disease evolution and implication of its incorporation into a survival scoring system. Blood 2010; 115: 5222–5231.
Gaidzik VI, Schlenk RF, Moschny S, Becker A, Bullinger L, Corbacioglu A et al. Prognostic impact of WT1 mutations in cytogenetically normal acute myeloid leukemia: a study of the German-Austrian AML Study Group. Blood 2009; 113: 4505–4511.
Damm F, Heuser M, Morgan M, Yun H, Grosshennig A, Göhring G et al. Single nucleotide polymorphism in the mutational hotspot of WT1 predicts a favorable outcome in patients with cytogenetically normal acute myeloid leukemia. J Clin Oncol 2010; 28: 578–585.
Ho PA, Zeng R, Alonzo TA, Gerbing RB, Miller KL, Pollard JA et al. Prevalence and prognostic implications of WT1 mutations in pediatric acute myeloid leukemia: A report from the Children’s Oncology Group. Blood 2010; 116: 702–710.
Call KM, Glaser T, Ito CY, Buckler AJ, Pelletier J, Haber DA et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms tumor locus. Cell 1990; 60: 509–520.
Yang L, Han Y, Saurez Saiz F, Minden MD . A tumor suppressor and oncogene: the WT1 story. Leukemia 2007; 21: 868–876.
Ariyaratana S, Loeb DM . The role of the Wilms tumour geneWT1 in normal and malignant haematopoiesis. Expert Rev Mol Med 2007; 9: 1–17.
Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, Peltonen L et al. Integrating common and rare genetic variation in diverse human populations. Nature 2010; 467: 52–58.
Komar AA . Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 2007; 8: 1075–1080.
Ma W, Kantarjian H, Zhang X, Wang X, Zhang Z, Yeh C-H et al. Mutation and single- nucleotide polymorphism (rs16754) in Wilms tumor-1 gene are independent prognostic factors in acute myeloid leukemia. Blood 2009; 114: 413.
Damm F, Heuser M, Ganser A, Krauter J . Reply to I.H.I.M Hollink et al. J Clin Oncol 2010; 28: e527–e528.
Renneville A, Boissel N, Helevaut N, Nibourel O, Terré C, Pautas C et al. Prognostic impact of Wilms tumor 1 single nucleotide polymorphism rs16754 in older patients with acute myeloid leukemia. Blood 2010; 161: 1113.
Ho PA, Kuhn J, Gerbing RB, Pollard JA, Zeng R, Miller KL et al. WT1 synonymous single nucleotide polymorphism rs16754 correlates with higher mRNA expression and predicts significantly improved outcome in favorable-risk pediatric acute myeloid leukemia: a report from the children's oncology group. J Clin Oncol 2011; 29: 704–711.
Ho PA, Alonzo TA, Gerbing RB, Sung L, Aplenc R, Pollard JA et al. WT1 snp rs16754 Genotype Predicts Treatment Related Mortality (TRM) in African-American and Asian Pediatric AML Patients: A Report From the Children's Oncology Group. Blood 2012; 120: 1385.
Abalkhail H, El-Solh H, Alseraihy A, Ayas M, Al-Ahmari A, Belgaumi AF et al. The AG Genotype of the Wilms Tumor-1 rs16754 SNP is associated with poor outcome in pediatric AML patients treated with stem cell transplantation but not in adults. Blood 2011; 118: 5327.
Luo S, Yu K, Yan QX, Shen ZJ, Wu JB, Chen HM et al. Analysis of WT1 mutations, expression levels and single nucleotide polymorphism rs16754 in de novo non-M3 acute myeloid leukemia. Leuk Lymphoma 2014; 55: 349–357.
Chen X, Yang Y, Huang Y, Tan J, Chen Y, Yang J et al. WT1 mutations and single nucleotide polymorphism rs16754 analysis of patients with pediatric acute myeloid leukemia in a Chinese population. Leuk Lymphoma 2012; 53: 2195–2204.
Hollink IH, van den Heuvel-Eibrink MM, Zimmermann M, Balgobind BV, Arentsen-Peters ST, Alders M et al. No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia. J Clin Oncol 2010; 28: e523–e526.
Renneville A, Boissel N, Helevaut N, Nibourel O, Terré C, Pautas C et al. Wilms' tumor 1 single-nucleotide polymorphism rs16754 does not predict clinical outcome in adult acute myeloid leukemia. Leukemia 2011; 25: 1918–1921.
Luna I, Such E, Cervera J, Barragán E, Jiménez-Velasco A, Dolz S et al. Analysis of SNP rs16754 of WT1 gene in a series of de novo acute myeloid leukemia patients. Ann Hematol 2012; 91: 1845–1853.
Becker H, Maharry K, Radmacher MD, Mrózek K, Metzeler KH, Whitman SP et al. Clinical outcome and gene- and microRNA-expression profiling according to the Wilms tumor 1WT1 single nucleotide polymorphism rs16754 in adult de novo cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study. Haematologica 2011; 96: 1488–1495.
Choi Y, Lee JH, Hur EH, Kang MJ, Kim SD, Lee JH et al. Single nucleotide polymorphism of Wilms' tumor 1 gene rs16754 in Korean patients with cytogenetically normal acute myeloid leukemia. Ann Hematol 2012; 91: 671–677.
Zhang DY, Yan H, Cao S, Zhang W, Li XL, Zeng H et al. Wilms Tumor 1 rs16754 predicts favorable clinical outcomes for acute myeloid leukemia patients in South Chinese population. Leuk Res 2015; 39: 568–574.
Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gotzsche PC, Ioannidis JP et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009; 339: b2700.
Komar AA, Lesnick T, Reiss C . Synonymous codon substitutions affect ribosome traffic and protein folding during in vitro translation. FEBS Lett 1999; 462: 387–391.
Qi XW, Zheng XD, Zong BG, Chen QQ, Zhang F, Yang XH et al. Association between WT1 polymorphisms and susceptibility to breast cancer: results from a case-control study in a southwestern Chinese population. Am J Cancer Res 2015; 5: 1234–1250.
Kim DH, Xu W, Ma C, Liu X, Siminovitch K, Messner HA et al. Genetic variants in the candidate genes of the apoptosis pathway and susceptibility to chronic myeloid leukemia. Blood 2009; 113: 2517–2525.
Carmichael SL, Ma C, Choudhry S, Lammer EJ, Witte JS, Shaw GM . Hypospadias and genes related to genital tubercle and early urethral development. J Urol 2013; 190: 1884–1892.
Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007; 315: 525–528.
Acknowledgements
This study was supported by grants from the ‘Instituto Carlos III’ (PIE13/00046) and the ‘Instituto Investigación Sanitaria La Fe’ (2013/0331) granted to Pharmacy and Hematology Departments and the Pharmacogenetics Unit of the ‘Instituto Investigación Sanitaria La Fe’ and the ‘Área del Medicamento’ of the ‘Hospital Universitari i Politècnic La Fe’, Valencia, Spain. We are grateful to Adrian Keukens for his editorial assistance on this manuscript.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Megías-Vericat, J., Herrero, M., Rojas, L. et al. A systematic review and meta-analysis of the impact of WT1 polymorphism rs16754 in the effectiveness of standard chemotherapy in patients with acute myeloid leukemia. Pharmacogenomics J 16, 30–40 (2016). https://doi.org/10.1038/tpj.2015.80
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/tpj.2015.80
- Springer Nature Limited
This article is cited by
-
The prognostic impact of Wilms tumor-1 polymorphism (rs16754) and human myeloid inhibitory C-type lectin-like receptor expression in cytogenetically normal-acute myeloid leukemia
Egyptian Journal of Medical Human Genetics (2021)